An interventional study of Supralimus-Core™ and Supralimus™ Core™ Sirolimus eluting stent in Coronary Artery Disease, sponsored by Sahajanand Medical Technologies Limited. Completed at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Sahajanand Medical Technologies Limited · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Coronary Artery Disease with a site in India — 6 open to participants now, 13 under way, 3 of them phase 3. Coronary Artery Disease · India.
Among the 62 studies in Coronary Artery Disease with a site in India, this one is the 33rd largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2006, is one of 24 with no phase, and was the 7th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →6 of the 62 studies in Coronary Artery Disease with a site in India are open now. Recruiting first, the newest first:
Seung-Jung Park · Sites in India, Hong Kong, Japan and 2 more countries
Ages 20+
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
Sunnybrook Health Sciences Centre · Sites in India, United States, Austria and 13 more countries
Ages 18+
Weill Medical College of Cornell University · Sites in India, United States, Australia and 23 more countries
Ages 18+ · Women only
Medtronic · Sites in India, United States, Argentina and 38 more countries
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is below the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 754 across the 43 interventional studies, 250 across the 19 observational. Of the 42 that completed or were terminated, 8 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 62 have an industry lead sponsor. The 10 most frequent:
Sahajanand Medical Technologies Limited is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Sahajanand Medical Technologies Limited has 7 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Coronary Artery Disease with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05829889Seung-Jung ParkFractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease | 2027-06 |
| NCT06386094Post Graduate Institute of Medical Education and Research, ChandigarhCardiac Dysfunction in Patients with Fatty Liver Disease | 2027-08-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 62 studies in Coronary Artery Disease with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
OBJECTIVES:
The primary objective of this study is to assess the safety and efficacy of the Supralimus - Core™ Sirolimus Eluting Stent in de novo native vessel obstructive coronary artery disease.
STUDY DESIGN:
This is a single centre, prospective study. Approximately 105 patients were enrolled in the study. Patients were followed for twelve months post-procedure. All patients were to have a repeat angiography at 8 months.
STUDY POPULATION:
The study population consisted of approximately 105 patients with de novo native vessel obstructive coronary artery disease with no specific criteria. Patients from the daily practice were included. Patients had to meet all eligibility criteria for inclusion into the study.
ENDPOINTS:
The primary safety endpoint of the study is defined as Major Adverse Cardiac Events (MACE) at 30 days.
The primary efficacy endpoint is the in-stent binary restenosis rate at 8-month follow-up determined by off-line Quantitative Coronary Angiography.
The following secondary efficacy endpoints were assessed
The following secondary safety endpoints were assessed:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Angiographic Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Supralimus™ Core™ Sirolimus eluting stent manufactured by Sahajanand Medical Technologies Limited intended to treat coronary artery disease.
Device: Supralimus-Core™ · Device: Supralimus™ Core™ Sirolimus eluting stent
Sirolimus Eluting Cobalt Chromium based coronary stent system
Supralimus™ Core™ Sirolimus eluting stent intended to treat coronary artery disease.
Primary safety endpoint: Major Adverse Cardiac Events (MACE)
Time frame: 30 days
Primary efficacy endpoint: In-stent binary restenosis rate determined by off-line Quantitative Coronary Angiography.
Time frame: 8 Month
Secondary safety endpoints: - MACE until 12 months, Device related SAEs until 12 months, Angiographic stent thrombosis: Subacute (after procedure until 30 days) and Late (after 30 days until 12 months)
Time frame: 12 months
Secondary efficacy endpoints: Angiographic, Procedure success; acute gain, MLD, % DS, LL, mean diameter; In-stent pre-,post,8-month follow-up; Clinically justified TLR at 12 months
Time frame: 12 months
The record gives a start of Jul 2006, a primary completion of Jul 2007 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sahajanand Medical Technologies Limited